(Q36815081)

16 August 2017

1 reference

title

Scleroderma lung: pathogenesis, evaluation and current therapy (English)

1 reference

16 August 2017

Jacob M van Laar

1

1 reference

16 August 2017

Jan Stolk

series ordinal

2

1 reference

16 August 2017

Alan Tyndall

series ordinal

3

1 reference

16 August 2017

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

67

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

985-996

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767070-00004

16 August 2017

exact match

0 references

cites work

Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767070-00004

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767070-00004

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767070-00004

Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance

21 January 2018

1 reference

12 December 2020

Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study

1 reference

12 December 2020

Pulmonary hypertension in autoimmune rheumatic diseases.

1 reference

12 December 2020

Skewing of the CD8+ T-cell repertoire in the lungs of patients with systemic sclerosis

1 reference

12 December 2020

Sildenafil citrate therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Blood and marrow stem cell transplants in autoimmune disease. A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT).

1 reference

12 December 2020

Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992-2001

1 reference

12 December 2020

Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension

1 reference

12 December 2020

Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases

1 reference

12 December 2020

P-wave amplitude and pulmonary artery pressure in scleroderma

1 reference

12 December 2020

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

1 reference

12 December 2020

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan

1 reference

12 December 2020

Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

1 reference

12 December 2020

High-dose immunosuppressive therapy and autologous progenitor cell transplantation for systemic sclerosis

1 reference

12 December 2020

Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study

1 reference

12 December 2020

HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients

1 reference

12 December 2020

High resolution computed tomography in early scleroderma lung disease

1 reference

12 December 2020

Pulmonary Arterial Hypertension

1 reference

12 December 2020

Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study

1 reference

12 December 2020

Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry

1 reference

12 December 2020

Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma

1 reference

12 December 2020

T-889C IL-1alpha promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis.

1 reference

12 December 2020

Expansion of selected V delta 1+ gamma delta T cells in systemic sclerosis patients.

1 reference

12 December 2020

Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis

1 reference

12 December 2020

Genetics of fibrosing lung diseases

1 reference

12 December 2020

Serial pulmonary function in systemic sclerosis

1 reference

12 December 2020

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

1 reference

12 December 2020

High resolution computed tomography in systemic sclerosis. Real diagnostic utilities in the assessment of pulmonary involvement and comparison with other modalities of lung investigation

1 reference

12 December 2020

Microchimerism and HLA-compatible relationships of pregnancy in scleroderma.

1 reference

12 December 2020

Outcomes of lung transplantation in patients with scleroderma.

1 reference

12 December 2020

Avian scleroderma: evidence for qualitative and quantitative T cell defects

1 reference

12 December 2020

The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia.

1 reference

12 December 2020

Predictors of survival in systemic sclerosis (scleroderma)

1 reference

12 December 2020

Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease

1 reference

12 December 2020

The lung in systemic sclerosis

1 reference

12 December 2020

Progressive generalized scleroderma: respiratory failure from primary chest wall involvement

1 reference

12 December 2020

Systemic sclerosis: hypothesis-driven treatment strategies

1 reference

12 December 2020

Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.

1 reference

12 December 2020

Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis

1 reference

12 December 2020

Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma

1 reference

12 December 2020

Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis

1 reference

12 December 2020

Structural features of interstitial lung disease in systemic sclerosis

1 reference

12 December 2020

Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma

1 reference

12 December 2020

Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography

1 reference

12 December 2020

Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide

1 reference

12 December 2020

Selective abnormalities in the thymic microenvironment associated with avian scleroderma, an inherited fibrotic disease of L200 chickens

1 reference

12 December 2020

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial

1 reference

12 December 2020

High resolution computed tomography as a predictor of lung histology in systemic sclerosis

1 reference

12 December 2020

Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium.

1 reference

12 December 2020

Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database

1 reference

12 December 2020

Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.

1 reference

12 December 2020

Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease

1 reference

12 December 2020

Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit

1 reference

12 December 2020

The endothelium in the pathogenesis of systemic sclerosis: is it primary or secondary?

1 reference

12 December 2020

Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.

1 reference

12 December 2020

Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.

1 reference

12 December 2020

Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases

1 reference

12 December 2020

Scleroderma patients with combined pulmonary hypertension and interstitial lung disease.

1 reference

12 December 2020

Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations

1 reference

12 December 2020

Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival

1 reference

12 December 2020

Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis)

1 reference

12 December 2020

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis

1 reference

12 December 2020

Predictors of end stage lung disease in a cohort of patients with scleroderma

1 reference

12 December 2020

Primary pulmonary hypertension: Current therapy.

1 reference

12 December 2020

Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies.

1 reference

12 December 2020

Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis

1 reference

12 December 2020

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

1 reference

12 December 2020

5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study

1 reference

12 December 2020

Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.

1 reference

12 December 2020

Severe restrictive lung disease in systemic sclerosis.

1 reference

12 December 2020

Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung

1 reference

12 December 2020

Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis

1 reference

12 December 2020

Evaluation and management of scleroderma lung disease using bronchoalveolar lavage

1 reference

12 December 2020

Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study

1 reference

12 December 2020

Cyclophosphamide versus placebo in scleroderma lung disease.

1 reference

12 December 2020

A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease

1 reference

12 December 2020

Bosentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

The lichen planus like and sclerotic phases of the graft versus host disease in man: an ultrastructural study of six cases

1 reference

12 December 2020

Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance

1 reference

12 December 2020

Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators.

1 reference

12 December 2020

Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls.

1 reference

12 December 2020

Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease

1 reference

12 December 2020

Haemopoietic stem cell transplantation for autoimmune diseases

1 reference

12 December 2020

Severe organ involvement in systemic sclerosis with diffuse scleroderma

1 reference

12 December 2020

CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.

1 reference

12 December 2020

Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test

1 reference

12 December 2020

Lung transplantation and systemic sclerosis

1 reference

12 December 2020

Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation

1 reference

12 December 2020

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

1 reference

12 December 2020

The changing face of severe scleroderma in five patients

1 reference

12 December 2020

Hemopoietic blood and marrow transplants in the treatment of severe autoimmune disease

1 reference

12 December 2020

Mortality in systemic sclerosis: an international meta-analysis of individual patient data

1 reference

12 December 2020

Identification of T cells in early dermal lymphocytic infiltrates in avian scleroderma

1 reference

12 December 2020

Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis

1 reference

12 December 2020

Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis.

1 reference

12 December 2020

Ambrisentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

10.2165/00003495-200767070-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

1050405299

0 references

1 reference